Formulation, Development and Evaluation of Fast Dissolving Oral Film of a
Atenolol Drug and validation by RP-HPLC Method using ICH Q2 guidelines

Balu S. Khandare* and Komal S. Wagh
Kasturi Shikshan Sanstha College of Pharmacy Shikrapur Pune, Maharashtra, India-412208

ABSTRACT

Now a days, fast dissolving dosage forms are gaining popularity, as this dosage form can be administered without water. Rapid dissolving property, avoiding first pass metabolism and majority of the drug is absorbed through buccal/oral mucosa in to systemic circulation. On oral administration of atenolol undergoes first pass metabolism results in reduced bioavailability up to (60%), so the objective of the present study was to formulate and evaluate fast dissolving oral films of atenolol to overcome the limitation of bioavailability and increase patient’s compliance. In recent studies oral films were prepared by solvent casting method using HPMC K15 as a film formers and PEG 400, glycerin as plasticizers and evaluated for mechanical properties, disintegration and in vitro dissolution. Good mechanical properties and in vitro drug release were shown by all formulations. The Comparing to other formulations, the optimized (FS) Formulation (HPMC K15, CCS and PEG 400) Exhibited drug release of 92.12% in 15 minutes which was significantly high. RP-HPLC is simple, fast, precise, sensitive, and reproducible (liquid chromatography) method was developed and validated for the analysis of atenolol drug formulation. Using C-18 HPLC column separation was carried out. This was maintained at ambient temperature. Analysis was carried out by using UV detector at the wavelength 228 nm. The RP-HPLC method was found to be linear over the concentration ranges from 50-100 μg/mL (r² = 0.999). Retention time for atenolol drug formulation was found to be 5.496min. LOQ of method was 5.7308μg/mL and LOD 2.5036μg/mL.

Keywords: Atenolol, Fast dissolving oral film, Bioavailability, Mechanical properties, C18, RP-HPLC, Methanol

INTRODUCTION

In the pharmaceutical industry rapidly dissolving or quick dissolving dosage forms have acquired great importance due to their unique properties and advantages. Within a minute these systems either dissolve or disintegrate, on contact little quantity of water or by chewing. This delivery system consists of a thin film, which is simply placed on the patient’s tongue or mucosal tissue, instantly wet by saliva; the film rapidly dissolves. Then it rapidly disintegrates and dissolves to release the medication for oral mucosal absorption. The major portion of the active ingredient is swallowed orally along the saliva and absorption takes place in the gastrointestinal tract subsequently making them particularly suitable for pediatrics and geriatric patients. In 1970’s the fast dissolving films were introduced as an alternative to the conventional tablet and capsule which require swallowing of the dosage form. By researchers the rapidly dissolving dosage forms are referred by various names such as quick disintegrating, orally disintegrating, mouth dissolve or melt in mouth dosage forms. There are specific advantages of these dosage forms including no need of water for disintegration, accurate dosing, ease of transport, handling, acceptable taste, rapid onset of action and patient compliance. The trans mucosal deliveries of metformin, dexa-methasone and levo-citrizine hydrochloride have proved their enhanced bioavailability over the conventional formulations. Solvent casting was proved to be reliable technique for the manufacturing of fast dissolving films. By this method the film strips prepared undergo instantaneous disintegration upon placing in buccal/oral cavity. The plasticizers present in fast dissolving films formulation, reduce the glass transition temperature and thereby enabling desired film qualities. Atenolol is chemically \((RS)-2-\{(2\text{-hydroxy}\text{-3-(propan-2\text{-ylamino}) propoxy}\} phenyl) acetamide. Atenolol is a beta blocker medication primarily used to treat high blood pressure and heart-associated chest pain. Other uses include the prevention of migraines and treatment of certain irreguar heart beats. It is taken by mouth or by injection into a vein. It can also be used with other blood pressure medications. Common side effects include feeling tired, heart failure, dizziness, depression,
and shortness of breath. Other serious side effects include bronchospasm. It is not recommended during pregnancy. Other medications are preferred when breastfeeding a young baby. It works by blocking β1-adrenergic receptors in the heart, thus decreasing the heart rate and workload. Atenolol is used for a number of conditions including hypertension, angina, long QT syndrome, acute myocardial infarction, supraventricular tachycardia, ventricular tachycardia, and the symptoms of alcohol withdrawal. Initial investigations were focused on the development of placebo fast dissolving films with good peel ability, appearance and a quick disintegration time. After choosing the components for the placebo film, atenolol loaded films were formulated. Although fast dissolving film is an attractive dosage form for the delivery of atenolol. Finally, HPMC and CCS were formulated and evaluated using fast dissolving films.

**MATERIAL AND METHOD**

Atenolol was received as a gift sample from Mylan Laboratories Limited, Hyderabad, India. HPLC grade methanol, ethanol and double distilled water as solvent were used for the other purpose. HPMC K15M, PEG-400, SSG, CCS was obtained from Mapromax, Life sciences Pvt. Ltd. Dehradun. Aspartame, citric acid was obtained from Loba Chemical Pvt Ltd (Mumbai, India). Hydrochloric acid was obtained from S. D. Fine Chem. Ltd., Mumbai. All other chemicals were purchased from Hi Media, Mumbai. All other chemicals used in this study including those stated were of analytical reagent (A.R.) grade.

**Drug-excipient compatibility study**

FTIR spectra of pure drugs, polymers used, and blends were recorded on KBr disk method using Brukers Alpha Spectrophotometer with IR solution software to confirm the compatibility between drug and excipient. Sample powder was thoroughly mixed by triturating with potassium bromide in a glass mortar with pestle and compressed into disks in a hydraulic press (Techno search Instruments, India). Over a spectral region from 4700 to 400 cm⁻¹ using 20 scans with 4 cm⁻¹ resolution, FTIR spectra of all the samples were recorded.

**Preparation of oral films**

Drug (atenolol) containing fast dissolving films were fabricated by the solvent casting method. The optimized amount of HPMC was dissolved in 5mL of water and stirrer continuously for 1 hour, optimized amount of Plasticizer and drug were dissolved in 95 % ethanol and then added to the polymeric solution. Polymeric solution was stirred for 30 min using magnetic stirrer and was kept in undisturbed condition till the entrapped air bubbles were removed. The aqueous solution was casted in a glass moulds having 2.5 x 2.5 cm, 10 films area and was dried at controlled room temperature (25-30°C, 45 % RH) as well as at increased temperature (microwave oven). The film took approximately 48 hr to dry at controlled room temperature. The dried film was carefully removed from the glass plates and was cut into size required for testing. The films were stored in air tight plastic bags till further use. Formulations were prepared using HPMC K15, PEG-400, SSG and CCS at different drug polymer ratios. Sample powder of the formulations was shown in table 1.

<table>
<thead>
<tr>
<th>Name of ingredients (mg for 12 strips)</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atenolol (mg)</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>HPMC K15 (mg)</td>
<td>700</td>
<td>80</td>
<td>1100</td>
<td>700</td>
<td>80</td>
<td>1100</td>
</tr>
<tr>
<td>Glycerin (mg)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PEG-400 (mg)</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>SSG (mg)</td>
<td>150</td>
<td>200</td>
<td>300</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CCS (mg)</td>
<td>-</td>
<td>-</td>
<td>200</td>
<td>300</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Aspartame (mg)</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Citric acid (mg)</td>
<td>110</td>
<td>110</td>
<td>110</td>
<td>110</td>
<td>110</td>
<td>110</td>
</tr>
<tr>
<td>DM water qs to (ml)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Evaluation**

The formulations were evaluated by the following tests.

**Thickness**

Randomly 20 films were selected and thickness was measured using vernier caliper at three different places.

**Weight variation**

For each formulation, three randomly selected patches were used. For weight variation test, 20 films from each batch were weighed individually by digital electronic balance and the average weight was calculated.

**Drug content analysis**

The patches (n = 3) of specified area were taken into a 10ml volumetric flask and dissolved in methanol and volume was made up with 10ml methanol. Subsequent dilutions were made and analyzed by UV spectrophotometer.
time intervals of 1, 2, 5, 10 and 15 minutes and replaced with equal volumes of phosphate buffer (pH 6.8). The collected samples were filtered through 0.45 μm membrane filter and the concentration of the dissolved atenolol was determined using UV-Visible spectrophotometer at 228 nm. The results were presented as an average of three such concentrations.

### Stability studies

Stability studies were carried out with optimized formulation which was stored for a period of one, two and three months at 40±2°C temperature and 75±5% relative humidity for a period 3 months. The % Assay of formulation was determined by U.V. spectrophotometer using calibration curve method. The % assay of film was found to slightly decrease at higher temperature.

### Physical appearance and texture analysis of the films

These parameters were checked simply with visual inspection of film and by feel or touch.

### In vitro disintegration

The film of (4.15 cm²) size (unit dose) was placed on a Petridis containing 10 ml of distilled water. The time required for the film to break was noted as cursive in vitro disintegration time.

### Measurement of mechanical properties

Microprocessor based advanced force gauge tensiometer (DS 2 series) equipped with a 50 kg load cell was used to determine the mechanical properties of OFDFs. Film of 60x10 mm² was fixed between two clamps separated by a distance of 3 cm. The lower clamp was held stationary and the strips were pulled apart by the upper clamp moving at a rate of 2 mm/sec until the strip broke. The force and elongation of the film at the point when the strip broke was recorded. The tensile strength and percent elongation values were calculated using the following formula.

\[
\text{Tensile strength} = \frac{\text{load at breakage}}{\text{film thickness} \times \text{film width}}
\]

\[
\% \text{Elongation} = \frac{\text{increase in length}}{100/\text{original length}}
\]

### HPLC METHOD VALIDATION

#### Determination of working wavelength (λmax)

10 mg of atenolol was weighed and transferred in to 100 mL volumetric flask and dissolved in methanol and then make a dilution of that stock solution. Prepare 10 μg/mL solutions by diluting 1 mL to 10 mL with methanol. Wavelength of maximum absorption for 10 μg/mL solution of the bulk drug in methanol was scanned using UV-Visible spectrophotometer within the range of 200-400 nm wavelength with methanol as reference. The absorption curve shows at 228 nm for atenolol formulation.

#### Linearity

For the linearity study were prepared suitable dilution (ranging from 50-100 μg/mL) of standard stock solution using mobile phase. Though linear response was obtained at lower concentrations for atenolol and higher concentration range was used to improve signal to noise ratio. Linearity was determined by analyzing five working standard solutions over the concentration range of 50-100 μg/mL for drug formulation concentration.

#### Limit of detection (LOD)

The limit of detection (LOD) is the smallest concentration that can be detected but not necessarily quantified as an exact value. LOD is calculated from the formula,

\[
\text{LOD} = 3.3\sigma/s
\]

Where, σ = standard deviation of the response

\[S = \text{slope of the calibration curve}\]

#### Limit of Quantification (LOQ)

The limit quantification (LOQ) is the lowest amount of analyte in the sample that can be quantitatively determined with precision and accuracy. LOQ is calculated from formula,

\[
\text{LOQ} = 10\sigma/s
\]

Where, σ = standard deviation of the response

\[S = \text{slope of calibration curve}\]

#### Accuracy

Accuracy of this method was carried out using one set of different standard addition methods at different concentration levels 80%, 100% and 120%, and then comparing the difference between the spiked value (theoretical value) and actual found value.

#### Precision

Five sets of aliquots with same concentration (90 μg/mL) were prepared and these solutions were analyzed to record any intra and inter day variations in the results. The results obtained for intra and inter day variations.

#### Robustness

Robustness of the proposed method for atenolol was carried out by the slight variation in flow rate, temperature and mobile phase ratio. The percentage recovery and RSD were noted for atenolol.

### Checking resolution of formulation

The column was saturated with the mobile phase (indicated by constant back pressure at desired flow rate). Standard solution of atenolol was injected to get the chromatogram. The retention time for atenolol was found to be 5.496 min. It is shown in the Table 2.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Ret. Time</th>
<th>Area</th>
<th>Height</th>
<th>Theoretical plate</th>
<th>Tailing factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atenolol</td>
<td>5.496</td>
<td>37957814</td>
<td>350811</td>
<td>38062.16</td>
<td>1.02</td>
</tr>
</tbody>
</table>
The data of the peak area vs drug formulation concentration were evaluated by linear regression analysis as shown in the Table 3 and calibration curve obtained after plotting drug formulation concentration vs area shown in the Fig.1 Linear regression analysis demonstrated that chromatogram response for the drug was highly linear ($r^2=0.999$) in the studied concentration range of 50-100 μg/mL. A typical chromatogram of atenolol (50 μg/mL) shown in Fig. 1.

**Fig.1 A typical chromatogram for drug formulation concentration (50 μg/mL)**

**Fig.2 Calibration curve of atenolol formulation**

**Table 3. Calibration of atenolol formulation**

<table>
<thead>
<tr>
<th>Sr no.</th>
<th>Concentration (μg/mL)</th>
<th>Peak area</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
<td>37957814</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>47957814</td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>57987814</td>
</tr>
<tr>
<td>4</td>
<td>80</td>
<td>68907814</td>
</tr>
<tr>
<td>5</td>
<td>90</td>
<td>78957814</td>
</tr>
<tr>
<td>6</td>
<td>100</td>
<td>88957814</td>
</tr>
</tbody>
</table>

**Precision**

The result depicted in the Table 6a, 6b indicated that the given method has sufficient precision as indicated by the corresponding values of %RSD ranging 0.13 for inter day studies respectively. The values of %RSD for both the studies are well below 1.0% constructing adequate precision.

**RESULT AND DISCUSSION**

Solubility of atenolol was freely soluble in various solvents like methanol and ethanol, also slightly soluble in 0.1N NaOH, soluble in water, 0.1N HCL and 6.8 pH phosphate buffers. The melting point of atenolol was 220-226°C and λmax of atenolol was found to be 228.0 nm by using U.V. spectrophotometer (shimadzu-1800) the general appearance, assay, weight variation and thickness of all the films were within acceptable limits table 4. The results for tensile strength, folding endurance, disintegrating time, % elongation and % of moisture were shown in Table 5. Tensile strength value of optimized formulation (F5) was 1.32±0.065 kg/cm2 and percent elongation 6.57±0.62. The folding endurance of the optimized oral fast dissolving formulation (F5) was 13.2±5.645. The formulations containing CCS were showing good results compared to SSG. The assay values of all the formulations were ranging from 90.25 to 98.89 %. The disintegration time was ranging between 52 to more than 92 sec. The final formulation shows better drug release (92.12%) compared to other formulation within 15 min(Figure 3). From the stability studies it was clearly observed that the drug showed good stability after subjecting to accelerated stress conditions and the polymers shown significantly compatibility with the drug. The cumulative percentage (%) drug release profile and the assay of the F5 formulation films indicates that the drug remain stable under the ASC without any significant change in its release profile and the drug content. RP-HPLC methods were developed and validated as per ICH guidelines Q2 (R1). The proposed methods can be successfully applied for atenolol Fast Dissolving Oral Film without any interference in quality control.

**Fig.3 In-vitro drug release study of Atenolol formulation**

**Table 4. Result of thickness and weight variation**

<table>
<thead>
<tr>
<th>F. code</th>
<th>General Appearance</th>
<th>Thickness in μm</th>
<th>Weight (mg) Mean ± S.D</th>
<th>% Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>Translucent</td>
<td>88±2</td>
<td>155±4</td>
<td>90.25±0.14</td>
</tr>
<tr>
<td>F2</td>
<td>Translucent</td>
<td>90±5</td>
<td>158±3</td>
<td>96.4±0.28</td>
</tr>
<tr>
<td>F3</td>
<td>Translucent</td>
<td>92±5</td>
<td>150±1</td>
<td>95.6±0.36</td>
</tr>
<tr>
<td>F4</td>
<td>Translucent</td>
<td>94±6</td>
<td>152±2</td>
<td>97.6±0.24</td>
</tr>
<tr>
<td>F5</td>
<td>Translucent</td>
<td>95±4</td>
<td>159±5</td>
<td>98.8±0.14</td>
</tr>
</tbody>
</table>
Table 5 Result of folding endurance, disintegrating time, tensile strength, % elongation &% of moisture content

<table>
<thead>
<tr>
<th>Code</th>
<th>Folding endurace (Times)</th>
<th>Disintegrating time (Sec)</th>
<th>Tensile strength in kg/cm²</th>
<th>% elongation Mean ± S.D</th>
<th>% of moisture content</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>105.25 ± 4.56</td>
<td>80 ± 6</td>
<td>0.62±0.056</td>
<td>5.94 ± 0.88</td>
<td>0.698 ± 0.111</td>
</tr>
<tr>
<td>F2</td>
<td>99.33 ± 7.67</td>
<td>75 ± 7</td>
<td>0.68±0.045</td>
<td>4.29 ± 0.67</td>
<td>0.647 ± 0.101</td>
</tr>
<tr>
<td>F3</td>
<td>111.02 ± 8.55</td>
<td>60 ± 6</td>
<td>1.21±0.012</td>
<td>2.24 ± 0.57</td>
<td>0.897 ± 0.142</td>
</tr>
<tr>
<td>F4</td>
<td>132.35 ± 6.45</td>
<td>52 ± 4</td>
<td>1.32±0.065</td>
<td>6.57 ± 0.62</td>
<td>0.898 ± 0.136</td>
</tr>
<tr>
<td>F5</td>
<td>120.66 ± 5.29</td>
<td>55 ± 5</td>
<td>1.26±0.045</td>
<td>3.21 ± 0.21</td>
<td>0.956±0.145</td>
</tr>
</tbody>
</table>

Table 6a. Intra-day Precision for atenolol formulation

<table>
<thead>
<tr>
<th>Concentration (μg/mL)</th>
<th>Peak area</th>
<th>Mean (n=5)</th>
<th>S.D.</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>78957745</td>
<td>77468861</td>
<td>12822.96</td>
<td>0.14</td>
</tr>
<tr>
<td>90</td>
<td>75620844</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>78528703</td>
<td>75100789</td>
<td>38917.53</td>
<td>0.15</td>
</tr>
<tr>
<td>90</td>
<td>76429855</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>75069865</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6b. Inter-day Precision for atenolol formulation

<table>
<thead>
<tr>
<th>Concentration (μg/mL)</th>
<th>Peak area</th>
<th>Mean (n=5)</th>
<th>S.D.</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>78957745</td>
<td>75100789</td>
<td>38917.53</td>
<td>0.15</td>
</tr>
<tr>
<td>90</td>
<td>75620844</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>78528703</td>
<td>75100789</td>
<td>38917.53</td>
<td>0.15</td>
</tr>
<tr>
<td>90</td>
<td>76429855</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>75069865</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 7 Limit of detection and Limit of quantification

<table>
<thead>
<tr>
<th></th>
<th>Limit of detection</th>
<th>Limit of quantification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.5036μg/mL</td>
<td>5.7308μg/mL</td>
</tr>
</tbody>
</table>

CONCLUSION

Oral fast dissolving films are more superior method to release drug. By using HPMC and PEG 400, the films are prepared and have shown good mechanical strength, to release drug, disintegrate the drug fast and also an enhancement of stability of drug. From result F5 formulation is considered as the best according to got result with low disintegration time and complete the drug release with in 15 min. the percent drug release and disintegration time was taken as responses for study which were found within the accepted ranges. In these formulation as the concentration of CCS was increased, both the disintegration and the drug release rates also increased. The disintegration and release rates were found to be faster for films prepared with lowest concentration of HPMC also with maximum concentration of super disintegrates. For pediatric, geriatric and also for general population, atenolol being administered in the form of fast dissolving films will be potential novel drug dosage form by providing faster release and better patient compliance. In this paper described for the determination of atenolol in formulation is simple, sensitive and reproducible.

ACKNOWLEDGEMENTS:

The authors are grateful to, the Principal and the Management of Kasturi Shikshan Sanstha College of Pharmacy Shikrapur Pune. The authors are thankful to Mylan laboratories Pvt. Ltd., Hyderabad (India) for providing gift sample.

REFERENCES


